Loading organizations...
Loading organizations...
Developing orally delivered small molecule inhibitors for various diseases.
Tvardi Therapeutics has raised $88.0M across 3 funding rounds.
Tvardi Therapeutics has raised $88.0M in total across 3 funding rounds.
Tvardi Therapeutics has raised $88.0M in total across 3 funding rounds.
Tvardi Therapeutics's investors include 683 Capital Management, ArrowMark Partners, Palkon Capital, Jamie McNab, Sporos Bioventures, National Cancer Institute.
Tvardi Therapeutics has raised $88.0M across 3 funding rounds. Most recently, it raised $74.0M Series B in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 23, 2021 | $74.0M Series B | 683 Capital Management, ArrowMark Partners, Palkon Capital, Jamie McNab | Sporos Bioventures |
| Jul 26, 2020 | $5.0M Grant | National Cancer Institute | |
| Sep 24, 2018 | $9.0M Series A |